Top

Published in:

01-04-2014 | Original Article

Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history of splenectomy: the significance of ADAMTS13 and graft function

Authors: Yu Nobuoka, Hideo Wada, Shugo Mizuno, Masashi Kishiwada, Masanobu Usui, Hiroyuki Sakurai, Masami Tabata, Toshihiko Kobayashi, Tsutomu Nobori, Shinji Uemoto, Shuji Isaji

Published in: International Journal of Hematology | Issue 4/2014

Abstract

The precise mechanism of prolonged thrombocytopenia following living donor liver transplantation (LDLT) remains unclear. To determine risk factors associated with prolonged thrombocytopenia following LDLT, with a focus on the activity of ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs member 13) and the influence of splenectomy. Adult LDLT patients were divided into two groups on the basis of platelet counts (100 × 10³/μL) on POD 14: high and low platelet (HP and LP) groups. Survival analysis was performed in the 100 patients, and ADAMTS13 activity and von Willebrand factor (VWF) levels in the plasma were measured in 65 adult recipients. The 6-month survival rate was significantly lower in the LP group (n = 36) than in the HP group (n = 62) (61.1 vs. 93.5 %). ADAMTS13 activity had been significantly lower in the LP group (n = 23) than in the HP group (n = 42). The VWF/ADAMTS13 ratio was significantly higher in the LP group than in the HP group. The independent risk factors for thrombocytopenia on POD14 were preoperative AT levels and ADAMTS13 activity on POD14. TPO levels on POD14 were significantly higher in the LP group than in the HP group, while those on POD28 in the LP group were significantly decreased, despite the low platelet levels. Irrespective of splenectomy history, platelet counts and ADAMTS13 activity in the LP group remained low until POD28, while VWF/ADAMTS13 ratio significantly increased until POD28. These results suggest that prolonged thrombocytopenia after LDLT was associated with not only a decrease in ADAMTS13 due to sinusoidal endothelial cell injury, but also low TPO production due to hepatocyte dysfunction, irrespective of history of splenectomy.

Kishi Y, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Kokudo N, et al. Splenectomy and preemptive interferon therapy for hepatitis C patients after living- donor liver transplantation. Clin Transpl. 2005;19(6):769–72.CrossRef

Marubashi S, Dono K, Miyamoto A, Takeda Y, Nagano H, Umeshita K, et al. Impact of graft size on postoperative thrombocytopenia in living donor liver transplant. Arch Surg. 2007;142(11):1054–8.CrossRefPubMed

Yoshizumi T, Taketomi A, Soejima Y, Ikegami T, Uchiyama H, Kayashima H, et al. The beneficial role of simultaneous splenectomy in living donor liver transplantation in patients with small-for-size graft. Transpl Int. 2008;21(9):833–42.CrossRefPubMed

Kobayashi T, Wada H, Usui M, Sakurai H, Matsumoto T, Nobori T, et al. Decreased ADAMTS13 levels in patients after living donor liver transplantation. Thromb Res. 2009;124(5):541–5.CrossRefPubMed

Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem. 2001;130(4):475–80.CrossRefPubMed

Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488–94.CrossRefPubMed

Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS 13), metalloproteinase involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276(44):41059–63.CrossRefPubMed

Plaimauer B, Zimmermann K, Völkel D, Antoine G, Kerschbaumer R, Jenab P, et al. Cloning, expression and characterization of the von Willebrand factor-cleaving pro- tease (ADAMTS 13). Blood. 2002;100(10):3626–32.CrossRefPubMed

Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New Engl J Med. 1998;339(22):1578–84.CrossRefPubMed

10.

Tsai HM, Lian EC. Antibody to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585–94.CrossRefPubMedPubMedCentral

11.

Uemura M, Fujimura M, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 2008;99:1019–29.PubMed

12.

Hyun J, Kim HK, Kim JE, Lim MG, Jung JS, Park S, et al. Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation. Thromb Res. 2009;124(1):75–9.CrossRefPubMed

13.

McCaughan GW, Herkes R, Powers B, Rickard K, Gallagher ND, Thompson JF, et al. Thrombocytopenia post liver transplantation. Correlations with pre-operative platelet count, blood transfusion requirements, allograft function and outcome. J Hepatol. 1992;16(1–2):16–22.CrossRefPubMed

14.

Chatzipetrou MA, Tsaroucha AK, Weppler D, Pappas PA, Kenyon NS, Nery JR, et al. Thrombocytopenia after liver transplantation. Transplantation. 1999;67(5):702–6.CrossRefPubMed

15.

Chang FY, Singh N, Gayowski T, Wagener MM, Mietzner SM, Stout JE, et al. Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoietin. Transplantation. 2000;69(1):70–5.CrossRefPubMed

16.

Ben Hamida C, Lauzet JY, Rézaiguia-Delclaux S, Duvoux C, Cherqui D, Duvaldestin P, et al. Effect of severe thrombocytopenia on patient outcome after liver transplantation. Intensive Care Med. 2003;29(5):756–62.CrossRefPubMed

17.

Vanhoutte PM. Platelets, endothelium and blood vessel wall. Experientia. 1988;44(2):105–9.CrossRefPubMed

18.

Iu S, Harvey PRC, Makowka L, Petrunka CN, Ilson RG, Strasberg SM. Markers of allograft viability in the rat: relationship between transplant viability and liver function in the isolated perfused liver. Transplantation. 1987;44(4):562–9.CrossRefPubMed

19.

Alkozai EM, Nijsten MW, de Jong KP, de Boer MT, Peeters PM, Slooff MJ, et al. Immediate postoperative low platelet count is associated with delayed liver function recovery after partial liver resection. Ann Surg. 2010;251(2):300–6.CrossRefPubMed

20.

Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93–100.CrossRefPubMed

21.

Buss DH, Cashell AW, O’Connor ML, Richards F 2nd, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med. 1994;96(3):247–53.CrossRefPubMed

22.

Ichikawa N, Kitano K, Shimodaira S, Ishida F, Ito T, Kajikawa S, et al. Changes in serum thrombopoietin levels after splenectomy. Acta Haematol. 1998;100(3):137–41.CrossRefPubMed

23.

Richards EM, Alexander GJ, Calne RY, Baglin TP. Thrombocytopenia following liver transplantation is associated with platelet consumption and thrombin generation. Br J Haematol. 1997;98(2):315–21.CrossRefPubMed

24.

Hernandez LA, Grisham MB, Twohig B, Arfors KE, Harlan JM, Granger DN. Role of neutrophils in ischemia-reperfusion induced microvascular injury. Am J Physiol. 1987;253:H699–703.PubMed

25.

Absher E, Labarrere CA, Carter C, Haag B, Faulk WP. The endothelial heparan sulfate-antithrombin III natural anticoagulant pathway in normal and transplanted human kidneys. Transplantation. 1992;53(4):828–34.CrossRefPubMed

26.

Vanhoutte PM. Platelets, endothelium and blood vessel wall. Experientia. 1988;44(2):105–9.CrossRefPubMed

27.

28.

Claus RA, Bockmeyer CL, Budde U, Kentouche K, Sossdorf M, Hilberg T, et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost. 2009;101(2):239–47.PubMed

29.

Claus RA, Bockmeyer CL, Sossdorf M, Lösche W. The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure? Curr Mol Med. 2010;10(2):236–48.CrossRefPubMed

30.

Ko S, Okano E, Kanehiro H, Matsumoto M, Ishizashi H, Uemura M, et al. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl. 2006;12(5):859–69.CrossRefPubMed

31.

Pereboom ITA, Adelmeijer J, van Leeuwen Y, Hendriks HGD, Porte RJ, Lisman T. Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. Am J Transpl. 2009;9(5):1189–96.CrossRef

32.

Mizuno S, Wada H, Hamada T, Nobuoka Y, Tabata M, Nobori T, et al. Lethal hepatic infarction following plasma exchange in living donor liver transplant patients. Transpl Int. 2011;24(7):e57–8.CrossRefPubMed

33.

Hori T, Kaido T, Oike F, Ogura Y, Ogawa K, Yonekawa Y, et al. Thrombotic microangiopathy-like disorder after living-donor liver transplantation: a single-center experience in Japan. World J Gastroenterol. 2011;17(14):1848–57.CrossRefPubMedPubMedCentral

34.

Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.CrossRefPubMed

35.

Nomura S, Ogami K, Kawamura K, Tsukamoto I, Kudo Y, Kanakura Y, et al. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol. 1997;25:565.PubMed

36.

Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost. 1995;74:521–5.PubMed

37.

Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood. 1995;86:419–31.PubMed

38.

Kaushansky K. Determinants of platelet number and regulation of thrombopoiesis. J Clin Invest. 2005;115(12):3339–47.CrossRefPubMedPubMedCentral

39.

Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98:10–23.CrossRefPubMed

40.

Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106(2):345–56.CrossRefPubMed

41.

Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood. 1996;87(6):2154–61.PubMed

Title: Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history of splenectomy: the significance of ADAMTS13 and graft function
Authors: Yu Nobuoka
Hideo Wada
Shugo Mizuno
Masashi Kishiwada
Masanobu Usui
Hiroyuki Sakurai
Masami Tabata
Toshihiko Kobayashi
Tsutomu Nobori
Shinji Uemoto
Shuji Isaji
Publication date: 01-04-2014
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 4/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-014-1543-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Primary bone marrow Hodgkin lymphoma in an HIV-negative patient

Successful transcatheter aortic valve implantation in a Hodgkin lymphoma patient with severe aortic stenosis

Thromboelastometry profile in children with beta-thalassemia

Guest editorial: recent progress in gene therapy

Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases

Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab

Keynote webinar | Spotlight on antibody–drug conjugates in cancer